Jun Dang,
Cancer Hospital Chinese Academy of Medical Sciences, Shenzhen Center
On January 8, 2026, the Proton Therapy Center at Shenzhen Hospital of the Chinese Academy of Medical Sciences Cancer Hospital successfully enrolled its final clinical trial patient, marking a significant milestone in the first proton therapy clinical trial within the public hospital system in South China. The center has now completed enrollment of all 47 trial subjects, laying a solid foundation for the formal integration of proton therapy into routine clinical practice.
The clinical trial, designed as a prospective single-center study, commenced participant recruitment in May 2025 and completed all enrollment within eight months. Subjects included tumors in multiple locations such as intracranial, head and neck, thoracic and abdominal, pelvic, spinal, and extremities, comprehensively validating the safety and efficacy of proton therapy. As the first public proton therapy facility in South China, the center is equipped with the globally advanced IBA Proteus® PLUS proton therapy system, featuring five treatment rooms and 300 beds across a total floor area of 35,000 square meters.
Professor Jin Jing, Director of the Proton Therapy Center, stated that the clinical trial strictly adheres to the “patient-oriented” principle, customizing personalized treatment plans for each participant through a multidisciplinary team (MDT). Currently 29 patients have successfully completed treatment and been without any serious site effect, which preliminarily validated both of proton therapy’s efficacy and safety.
It is noteworthy that the center has opened a free proton therapy consultation clinic, providing professional evaluations to thousands of cancer patients. According to the trial protocol, after completing the three-month short-term follow-up for all patients, the center will submit the research data to the National Medical Products Administration. Upon approval of the diagnostic and therapeutic license, proton therapy will be officially applied to routine clinical treatment, marking a “from zero to one” breakthrough for public hospitals in South China in this field. In the future, the center will continue to accumulate long-term follow-up data, strengthen medical collaboration, and promote the standardization as well as the accessibility of proton therapy technology, and transfer it to a broader caner patient population.